PHARMA 310505
ActiveSummary
PHARMA 310505 has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €413,071 and a net result of €28,950. Equity is growing by about 83% per year across the filed financial years. Its solvency ranks better than 52% of 12,737 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Articles of association
What the company does
- Name clauseThe name the company operates under according to its articles.
- Pharma 310505
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest, kan bij enkel besluit van het bestuursorgaan administratieve zetels,agentschappen,werkhuizen,stapelplaatsen en bijkantoren…” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Één of meer bestuurders, elke bestuurder kan aan iedere andere bestuurder schriftelijke volmacht geven door alle middelen van overdracht om…” (deed in Dutch)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Register van aandelen op naam op vennootschapszetel met vermeldingen voorgeschreven door Wetboek van vennootschappen en verenigingen, op…” (deed in Dutch)
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- One provision in the deed
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Last Wednesday of June at 10:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- One provision in the deed
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “31, ontbinding om welke reden en op welk ogenblik ook” (deed in Dutch)